Two Antidepressants Haven't Worked: What a Psychiatrist Considers Next
When two antidepressants have not helped, a psychiatrist usually starts by checking whether those trials were truly adequate and whether the diagnosis is right, before adding anything new. If the depression is genuinely not responding, the main options are optimizing the dose, switching, adding a second medication, adding psychotherapy, and, for treatment-resistant depression, esketamine, TMS or ECT.
Two failed trials is common, and it does not mean nothing can help. NICE tells clinicians to reassure people that although treatment has not worked so far, other treatments can be tried and may be effective.
What "treatment-resistant" actually means
The FDA and the European Medicines Agency use the most common definition of treatment-resistant depression (TRD): an inadequate response to at least two antidepressants, despite adequate treatment trials and taking the medication as prescribed. A 2023 expert review in World Psychiatry estimated that at least 30% of people with depression meet this definition, while noting there is still no single agreed definition.
The same review points out that a significant share of people labeled treatment-resistant are actually "pseudo-resistant": the earlier trials were too short, the dose too low, or the medication was not taken consistently. That is why the first step is a careful look back rather than a new prescription.
Step one: re-check before changing course
NICE recommends that when depression has not responded, the clinician first asks whether personal, social or environmental factors, physical illness or another mental health condition might explain it, and whether there have been problems sticking with the plan, such as stopping because of side effects. If response is still poor, the guideline says to review the diagnosis and consider other or coexisting conditions.
| What to re-check | Why it matters |
|---|---|
| Dose and duration of each trial | Antidepressants usually take four to eight weeks to work. A trial stopped early or at a low dose may not count. |
| Adherence | Missed doses, or stopping because of side effects, can make a medication look ineffective. |
| Bipolar disorder | Antidepressants can trigger mania or hypomania in people at risk, and labels ask prescribers to screen for bipolar disorder first. Bipolar depression is treated differently. |
| Medical contributors | Thyroid problems, untreated sleep apnea, anemia, chronic pain and some medications can produce or worsen depressive symptoms and are worth ruling out. |
| Alcohol and other substances | Regular use can blunt response to treatment and disturb sleep. |
| Ongoing stressors | Relationship conflict, work strain, caregiving or trauma can keep symptoms going whatever the medication. |
Does each trial count? A quick checklist
Before calling a medication a failure, a psychiatrist will usually ask the same handful of questions about each past trial. You can answer most of them yourself ahead of time.
| Question | Why it matters |
|---|---|
| Did you reach a therapeutic dose, not just the starting dose? | NICE's review point for no response is four weeks at a therapeutic dose, not four weeks from the first pill |
| How long did you stay at that dose? | Antidepressants usually take four to eight weeks to work |
| Did you take it most days as prescribed? | The FDA and EMA definition of resistance assumes the medication was taken as prescribed |
| Did side effects end the trial early? | That is an intolerance, which points toward a different drug, not necessarily resistance |
| Was it during this episode of depression? | The FDA-approved TRD indication for olanzapine with fluoxetine refers to two adequate trials of different antidepressants in the current episode |
| Was there any benefit at all, even partial? | Partial benefit changes the options; adding a treatment may be considered alongside switching |
It is common to find that one of two "failed" trials never reached a full dose or was stopped after two or three weeks. That is not a mistake on your part; it simply changes the next step.
Bringing a clear medication history to this review saves time and avoids repeating trials that already failed. How to prepare your medication history lists what to gather. The site's pages on bipolar disorder versus depression and lab tests a psychiatrist may order cover two of the most common things to rule out.
Optimize, switch or add on
If the trials were adequate and the diagnosis holds, NICE lists several medication strategies: increasing the dose within the licensed range if the drug is well tolerated, switching to another drug in the same class, or switching to a different class. It cautions that higher doses may not be more effective and can increase side effects. The expert review in World Psychiatry describes the evidence for extending a trial, switching and combining antidepressants as mixed.
In practice, the choice often follows the pattern of response:
- No benefit at all, or side effects you cannot live with: switching is often favored.
- A real but partial benefit: adding a second treatment keeps what is working while targeting what is left.
- Good response that faded: dose, adherence, new stressors and medical changes are re-checked first.
Switching between antidepressants is usually done gradually, sometimes with a period of overlap called cross-tapering, and some combinations need a gap between drugs to be safe. This is one of the clearest reasons never to make changes on your own: the sequence and timing matter, and your prescriber can plan a switch that limits withdrawal symptoms and interactions.
The site's guide to SSRI dose optimization covers the dose question in more detail.
What STAR*D does and does not tell us
STAR*D, a large US study run in real-world clinics, gave people up to four successive treatment steps. Its main 2006 report gave remission rates of 36.8%, 30.6%, 13.7% and 13.0% for steps one to four, and a cumulative remission rate of 67%. People who needed more steps also relapsed more often during follow-up.
The caveats matter. A 2023 reanalysis of the patient-level data, using the outcome measure specified in the study protocol, found a cumulative remission rate of 35.0%, about half the published figure. STAR*D was also open-label, so patients and clinicians knew which treatment was being given. The lasting lessons are more modest: each additional step still helps some people, the odds per step decline, and relapse risk rises, which argues for making each trial count.
In STAR*D's third step, adding lithium or thyroid hormone (T3) to the antidepressant produced remission in 15.9% and 24.7% of participants respectively, a difference that was not statistically significant; lithium caused more side effects.
Augmentation options
| Add-on | US regulatory status for depression | Things to discuss |
|---|---|---|
| Aripiprazole | FDA-approved as adjunctive treatment of major depressive disorder | Drugs in this class can cause weight gain and blood sugar and lipid changes, which are monitored |
| Brexpiprazole | FDA-approved as add-on to antidepressants for MDD in adults | Label warnings include weight gain, blood sugar and lipid changes, and tardive dyskinesia |
| Cariprazine | FDA-approved as add-on to antidepressants for MDD in adults | Same class considerations |
| Quetiapine extended-release | FDA-approved as adjunctive therapy for MDD | Same class considerations |
| Olanzapine with fluoxetine (one combination capsule) | FDA-approved for treatment-resistant depression | Weight gain and blood sugar and lipid changes are label warnings |
| Lithium | Off-label; FDA-approved for bipolar I disorder | Requires blood levels and monitoring of kidney and thyroid function |
| T3 (liothyronine) | Off-label; FDA-approved for hypothyroidism | Ask how it will be monitored |
| A second antidepressant from another class | No FDA approval for the combination itself | NICE gives adding mirtazapine or trazodone to an SSRI as examples |
The expert review notes that some second-generation antipsychotics have proven effective as add-ons for people with a partial response, although only the olanzapine-fluoxetine combination has been studied in TRD as the FDA defines it. NICE suggests that combination medication strategies be considered with specialist input, and that people be told about the possible increase in side-effect burden.
Adding psychotherapy
Psychotherapy is an under-used next step. The 2023 review concluded that manual-based psychotherapies, while not established as effective on their own in TRD, offer significant symptom relief when added to antidepressants. NICE lists switching to or adding a psychological therapy among the options after limited response to medication, alone or combined with a change in medication.
If you have not yet had a full course of structured therapy, such as CBT or interpersonal therapy, this is often worth trying before more intensive treatments. Medication, therapy or both summarizes the evidence for combining them.
Special situations that change the plan
Possible bipolar disorder
If you have ever had days of unusually high energy, little need for sleep, racing thoughts or uncharacteristic risk-taking, say so, even if it was years ago. Depression that is part of bipolar disorder is treated differently, and antidepressants alone can be risky; bipolar depression treatment options covers the approach.
Depression with psychotic symptoms
Hearing voices, holding fixed false beliefs such as guilt or ruin, or severe paranoia during depression changes the picture. NICE recommends referral to specialist mental health services and suggests considering an antidepressant combined with an antipsychotic, noting that antipsychotic use for depression was off-label for some antipsychotics when the guideline was written. This needs prompt, specialist care rather than another outpatient trial.
Long-standing depression
Some people have had low mood for years and have come to see it as their personality. NICE notes that people with chronic depressive symptoms may not have sought treatment before and may not realize they have depression. For chronic depression, structured psychotherapy, alone or combined with medication, is part of the guideline's options.
Depression after childbirth
Postpartum depression has its own FDA-approved treatment. Zuranolone is FDA-approved for postpartum depression in adults as a 14-day course, and its boxed warning says patients should not drive or do other hazardous activities until at least 12 hours after each dose during the course. Breastfeeding, sleep loss and infant care all shape the choice; postpartum depression treatment options compares them.
Midlife and perimenopause
Depression that begins or worsens around perimenopause may respond to a different plan, including hormone therapy in some cases. Perimenopause depression: HRT or antidepressants explains the evidence.
Young adults
Antidepressant labels carry a boxed warning about suicidal thoughts and behaviors in children, adolescents and young adults, and ask for close monitoring when a medication is started or changed. Each switch or new add-on restarts that monitoring period, so younger patients need a clear way to reach the prescriber during each change.
Newer antidepressants worth asking about
Several medicines have been approved or recommended more recently than the drugs most people try first. They are not specific treatments for TRD, but they work differently and may be reasonable next options.
- Dextromethorphan with bupropion (Auvelity) is FDA-approved for major depressive disorder in adults and carries the antidepressant boxed warning about suicidal thoughts and behaviors. It is not approved for pediatric patients.
- NICE lists vortioxetine as an option when there has been no or limited response to at least two antidepressants in the current episode.
How these compare with older options, including side effects and interactions, is covered in newer antidepressants compared. The practical details of moving from one drug to another are in switching antidepressants: what to expect, and a fuller comparison of add-ons is in antidepressant augmentation options.
Esketamine, TMS and ECT
Esketamine nasal spray (Spravato) is FDA-approved for treatment-resistant depression in adults, either on its own or with an oral antidepressant. A 2025 randomized trial in JAMA Psychiatry found that esketamine without an oral antidepressant improved symptoms more than placebo at four weeks in adults with TRD. It is available only through a REMS program, given in certified healthcare settings under direct observation, with monitoring for at least two hours after each dose because of risks including sedation, dissociation and misuse.
Transcranial magnetic stimulation (TMS) devices are FDA-cleared for treatment-resistant depression; the first device was cleared for depression in 2008. Electroconvulsive therapy (ECT) is FDA-cleared for severe depressive episodes, and NICE suggests considering it for severe depression when other treatments have not worked or a rapid response is needed. The 2023 review describes ECT as an effective acute and maintenance treatment in TRD.
The wider map of these options is in depression treatment options compared.
Spravato is also FDA-approved, in conjunction with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. Recommendations differ by country: NICE does not recommend esketamine nasal spray for treatment-resistant depression in its technology appraisal guidance for England, which reflects a cost and evidence judgment for the health service there rather than an FDA safety finding. In the US, access often depends on insurance coverage and on finding a certified treatment center.
Things worth treating directly
Some problems keep depression going regardless of which antidepressant you take. Treating them directly can make the next trial more likely to succeed.
- Insomnia: persistent poor sleep is common in depression and can outlast it. Insomnia has its own effective treatments, including CBT for insomnia; insomnia treatment options compared explains them.
- Alcohol and cannabis: regular use can blunt response and disturb sleep. An honest account helps the psychiatrist interpret what has and has not worked.
- Medical conditions: thyroid disease, anemia, vitamin deficiencies, sleep apnea and some medications can mimic or worsen depression. Medical causes to rule out lists the usual checks.
- Activity and routine: NICE includes group exercise among its treatment options for less severe depression, and regular activity and structure support recovery at any severity.
People at this stage often ask about genetic testing to pick the next medication. What those tests can and cannot tell you, and what insurers cover, is in pharmacogenomic testing: insurance and limits.
Common mistakes at this stage
- Counting a trial that never reached a therapeutic dose, or lasted only a couple of weeks.
- Switching every few weeks, so no medication gets a fair trial.
- Stopping a medication suddenly between prescribers, which can cause withdrawal symptoms; NICE notes these usually go away within one to two weeks but can sometimes be more difficult.
- Adding medications without stopping ones that clearly did not help, which raises side effects without adding benefit.
- Never trying structured psychotherapy, even though manual-based psychotherapy added to antidepressants offers significant relief in treatment-resistant depression.
- Leaving out past high-energy periods, alcohol use or a family history of bipolar disorder, which changes the diagnosis and the plan.
When something finally works
Once you respond, the goal shifts to staying well. NICE advises explaining to people that antidepressant treatment might need to continue for at least six months after symptoms remit, with regular reviews. People who needed several steps to respond were more likely to relapse in STAR*D, so it is worth agreeing with your psychiatrist on a relapse-prevention plan: which early warning signs to watch for, how long to continue treatment, and how any future taper will be done. Mindfulness-based cognitive therapy for depression relapse describes one psychological approach to preventing recurrence.
Who should be managing this
Many people start antidepressants with a primary care clinician, and for a first uncomplicated episode that can work well. After two trials without enough benefit, the decisions get more technical: re-checking the diagnosis, choosing between add-on medications that need monitoring, and judging when to refer for esketamine, TMS or ECT. NICE suggests that combination medication strategies be considered with a specialist's involvement.
That does not mean your current clinician has done anything wrong. It means the next steps benefit from someone who manages these medications routinely. Psychiatrist or primary care for your antidepressant covers how to decide, and how to make the handover smooth.
Keep a simple record between visits
Treatment decisions at this stage are only as good as the information behind them. A brief weekly record makes each visit more productive:
- A symptom score from a standard questionnaire such as the PHQ-9, which rates nine depression symptoms and is widely used to track severity.
- Sleep, energy, appetite and ability to work or study, in a word or two each.
- Any side effects, when they started, and whether they are easing.
- Missed doses, alcohol or other substance use, and major stressors that week.
Patterns over several weeks are more informative than how you feel on the day of the appointment.
Questions to bring to your psychiatrist
- Were my previous trials long enough and at a high enough dose to count?
- Have we ruled out bipolar disorder, thyroid problems, sleep apnea and other medical causes?
- Given my response so far, do you favor switching, adding a medication, or adding therapy, and why?
- What side effects and monitoring come with that choice?
- How will we measure whether it is working, and when will we decide?
- At what point would you refer me for esketamine, TMS or ECT?
If your current prescriber cannot answer these, a second opinion on your medication can help. Do not stop, start or change medications on your own while you sort this out; any change should be planned with the prescriber.
If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.
At this practice, psychiatric evaluation and medication management sit alongside psychotherapy, lab testing, and nutrition and lifestyle psychiatry. The 75-minute Health Strategy Session with Dr. Lewis includes a review of health history and treatment options, and can include discussion of bloodwork where appropriate. See the Choosing Psychiatric Care guide for ways to start.
Frequently asked questions
Does two failed antidepressants mean I have treatment-resistant depression?
Only if both trials were adequate in dose and length and the medication was taken as prescribed. Many people who seem treatment-resistant turn out to have had trials that were too short or too low in dose.
Is switching or adding a medication better?
Neither is better for everyone. Switching is often favored when there was no benefit or side effects were intolerable; adding a second treatment is often favored when there was a partial benefit. Your psychiatrist should explain the reasoning for your situation.
Should a psychiatrist take over from my primary care doctor now?
Often, yes. After two unsuccessful trials, a psychiatrist can re-check the diagnosis and manage add-on medications and referrals. See psychiatrist or primary care for antidepressants.
Is esketamine the same as ketamine?
Esketamine is a form of ketamine developed as a nasal spray. It is FDA-approved for treatment-resistant depression and given only in certified healthcare settings under a REMS program.
How long should each new step be given?
Long enough to judge fairly. Antidepressants usually take four to eight weeks, and NICE suggests reviewing if there has been no response at all after four weeks at a therapeutic dose.
Can a genetic test tell me which antidepressant will work?
Not reliably on its own. Some tests show how your body may process certain medications, which can inform dosing or side-effect risk, but they do not guarantee a response. Ask your psychiatrist what a result would actually change in your plan; pharmacogenomic testing: insurance and limits covers the details.
If a new medication works, how long will I need to take it?
That is a decision to make with your prescriber. NICE advises that antidepressant treatment might need to continue for at least six months after symptoms remit, with regular reviews, and that any stopping should be planned and gradual.
Sources
- Depression in adults: treatment and management (NG222), Recommendations. National Institute for Health and Care Excellence, 2022. nice.org.uk
- Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry (McIntyre et al.), 2023. pubmed.ncbi.nlm.nih.gov
- Mental Health Medications. National Institute of Mental Health, 2023. nimh.nih.gov
- Wellbutrin XL (bupropion extended-release) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry (Rush et al.), 2006. pubmed.ncbi.nlm.nih.gov
- What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol. BMJ Open (Pigott et al.), 2023. pubmed.ncbi.nlm.nih.gov
- A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. American Journal of Psychiatry (Nierenberg et al.), 2006. pubmed.ncbi.nlm.nih.gov
- Abilify (aripiprazole) tablets prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
- Rexulti (brexpiprazole) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Vraylar (cariprazine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
- Seroquel XR (quetiapine extended-release) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Lithium carbonate prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Liothyronine sodium tablets prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Spravato (esketamine) nasal spray prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry (Janik et al.), 2025. pubmed.ncbi.nlm.nih.gov
- Brain Stimulation Therapies. National Institute of Mental Health, 2024. nimh.nih.gov
- The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine (Kroenke et al.), 2001. pubmed.ncbi.nlm.nih.gov
- Olanzapine and fluoxetine capsules prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Zurzuvae (zuranolone) capsules prescribing information. Biogen / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
- Auvelity (dextromethorphan and bupropion) extended-release tablets prescribing information. Axsome Therapeutics / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.
The information provided on this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A Message From Dr. Lewis If you’ve been struggling with depression or anxiety, I want you to know something important:
The Conversation That Surprised Me A few years ago, I had a patient named Greg who’d been on escitalopram (Lexapro)
You’re Not Meant to Go Through Life Alone In our increasingly connected yet often isolating world, you might sometimes feel